Abeona Therapeutics Inc. (ABEO) Stock Rating Reaffirmed by Maxim Group
Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating restated by equities researchers at Maxim Group in a research note issued to investors on Thursday. They presently have a $14.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $8.00. Maxim Group’s price target indicates a potential upside of 136.89% from the stock’s current price.
Other equities analysts have also recently issued research reports about the company. FBR & Co restated a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a report on Friday, August 26th. Rodman & Renshaw restated a “buy” rating and set a $17.00 price target on shares of Abeona Therapeutics in a report on Sunday, August 21st. Cantor Fitzgerald started coverage on Abeona Therapeutics in a report on Wednesday, September 7th. They set a “buy” rating and a $21.00 price target for the company. Finally, Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 21st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $14.00.
Abeona Therapeutics (NASDAQ:ABEO) traded up 1.52% during mid-day trading on Thursday, reaching $6.00. The company had a trading volume of 163,884 shares. Abeona Therapeutics has a 1-year low of $2.05 and a 1-year high of $6.80. The firm has a 50-day moving average of $4.80 and a 200 day moving average of $3.25. The company’s market capitalization is $201.27 million.
Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. On average, analysts predict that Abeona Therapeutics will post ($0.73) earnings per share for the current fiscal year.
In other Abeona Therapeutics news, Director Todd Wider purchased 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 20th. The stock was purchased at an average cost of $5.48 per share, with a total value of $27,400.00. Following the purchase, the director now owns 75,000 shares of the company’s stock, valued at $411,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.00% of the stock is owned by insiders.
Several large investors have recently modified their holdings of the company. BlackRock Fund Advisors raised its stake in shares of Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock worth $774,000 after buying an additional 23,734 shares in the last quarter. Royce & Associates LP raised its stake in shares of Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 76,678 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 10,082 shares in the last quarter. Finally, Sabby Management LLC raised its stake in shares of Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 34,108 shares in the last quarter. 19.95% of the stock is owned by hedge funds and other institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.